Cancer Immunotherapy Market to Register Double-digit Growth in 2020, as Conventional Therapies Lose Sheen, Finds Fact.MR
Dec 12, 2019
The study indicates that the players in the cancer immunotherapy market space can expect a marginal rise in the demand for cancer immunotherapy, with an estimated CAGR of 15% during the forecast period (2020-2025).
Rockville, United States - December 12, 2019 /MarketersMedia/ —
A recent report published by Fact.MR points towards disequilibrium in the distribution of cancer immunotherapy in developing and developed regions. In the U.S., high frequency of knowledge-based awareness campaigns encourages individuals to undergo cancer diagnostics, and government-led insurance plans cover high treatment spending.
In stark contrast, developing countries such as Brazil and Argentina lack primary cancer treatment tools. A similar scenario is witnessed in South Africa, where the mortality rate is high, owing to the late diagnosis of cancer. Developing countries of Asia Pacific with high population density and average penetration of quality treatment are serving as high potential cancer immunotherapy markets.
Analysing a number of dynamics, the Fact.MR study foresees high opportunities in developing regions such as Latin America, the Middle East & Africa, and Asia Pacific, and projects nearly 1.7X growth of the cancer immunotherapy market during the forecast period (2020-2025).
Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=4367
Key Highlights of Cancer Immunotherapy Market Study
- Qualitative approach of therapeutic development turns highly cost-intensive for players in the cancer immunotherapy market. Additionally, high product rejection in trial phases leads to huge losses, which discourages manufacturers towards the development of new therapeutics.
- Progressive rise in the popularity of generic drugs, on account of the affordability factor, is diverting the patient base from spending on branded drugs, thereby weakening the sales prospects of manufacturers.
- Incentives offered by central healthcare authorities on development of 'orphan drugs' are encouraging established manufacturers to venture into this space.
- Though hospitals are holding a dominant position as end users in the cancer immunotherapy market, a shift of patients towards clinics will remain noteworthy for market players, on account of shorter wait windows and improvements in healthcare services offered by these institutions.
A healthcare industry expert at Fact.MR infers, “Manufacturers can increase focus towards the development of anticancer drugs, particularly for lung cancer, given the influence of the multitude of drivers adversely impacting the health of lungs. By 2025, the adoption of immunotherapies to treat lung cancer would be valued at US$ 38 Bn.”
Request Research Methodology- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4367
Threat from Conventional Therapies to Remain Growth Barrier for Manufacturers
Lack of proper awareness regarding advanced cancer treatment implies that, conventional therapies such as radiography and chemotherapy will not go obsolete, at least in the near future. Manufacturers are intensifying efforts towards product innovation to achieve orphan drug status and ensure high marketability.
Pfizer, Inc. best illustrates this strategy. The company has taken multiple initiatives such as collaborations, alliances, mergers, and licensing agreements to launch biologics and receive orphan status for its products. Monetary support from governments to manufacturers, with an intent to develop a promising pipeline of cancer therapeutics, is attracting a large number of new entrants, especially in North America. However, leading players would encounter a low threat of new entrants, on account of their high developmental knowhow and strong distribution networks.
Find More Valuable Insights on Cancer Immunotherapy Market
Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global cancer immunotherapy market, presenting historical demand data (2016-2019), and forecast statistics for the period of 2020-2025. The study divulges compelling insights on the cancer immunotherapy market on the basis of therapy (monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others), cancer type (lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer, and others), and end user (hospitals, ambulatory surgical centres, cancer research centres, and clinics), across five major regions.
To get more insights on cancer immunotherapy market, visit- https://www.factmr.com/report/4367/cancer-immunotherapy-market
About the Healthcare Division at Fact.MR
The healthcare team at Fact.MR assists clients with unique business intelligence needs on a global level. With a repertoire of over 1,000 reports and 1 million+ data points, the team has analysed the healthcare industry to a micro-level across 50+ countries for over a decade. The team provides end-to-end research and consulting services to help keep clients at the top of the game. Reach out to us to know how we can help.
Contact Info:
Name: James Hilton
Email: Send Email
Organization: Fact.MR
Website: https://www.factmr.com/
Source: MarketersMedia
Release ID: 88939026
More News
Holiday Travel Costs Are Soaring. Here’s How to Save.
As airfares and gas prices surge, here’s how you can extend your travel budget.
What is the Budget and what could be in it?
Chancellor John Healey will set out his plans for UK taxes on 28 October.
U.S. Pensions Are Riding the A.I. Wave. For Better or Worse.
As exuberance around the technology stokes fears of a bubble, the nation’s public pensions are starting to grapple with their role — and their risks.
In Anthropic I.P.O., Goldman and Morgan Stanley Slug It Out for Top Bank
Anthropic named the Wall Street firms lead underwriters on its upcoming public offering, a role that will generate generous fees and enormous prestige.
Apple to replace iPhone Duos affected by screen problem
Photos shared online showed faults appearing on the screens of Apple's first foldable device.
In Anthropic I.P.O., Goldman and Morgan Stanley Slug It Out for Top Bank
Anthropic named the Wall Street firms lead underwriters on its upcoming public offering, a role that will generate generous fees and enormous prestige.
The Fed Is Expected to Hold Rates Steady. Warsh Will Have to Explain Why.
Inflation is moving in the wrong direction and the labor market remains stable, a combination that bolsters the case for higher interest rates.
Why Is Halloween Candy So Expensive?
The average cost of a 100-piece bag has jumped 71 percent in the last five years. Consumers are thinking twice about what they’ll spend.
In the A.I. ‘Robogym,’ Machines Train to Be More Like Humans
Germany’s Neura is one of the companies at the forefront of efforts to use artificial intelligence in robotics, and crucial to whether Europe can close the gap with China.
Rise in sales of radios and tinned foods, say retailers, after call to stock up
Figures obtained by BBC Newsnight show large spikes in sales of torches, radios and power banks.
Will the Budget pass Burnham's Makerfield test?
People in the prime minister's constituency say rising costs are squeezing household finances.
First-time buyers hoping for help from the Budget
Aspiring homeowners say rent, rising costs and house prices are delaying plans to buy.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.